Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Pancreatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, Follicular 1Liver Neoplasms 1Leukemia 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Sunitinib 27Nivolumab 26pembrolizumab 23Sorafenib 17Everolimus 14Cyclophosphamide 13Interleukin-2 10Bevacizumab 10Radiosurgery 9spartalizumab 8pazopanib 7atezolizumab 7Ipilimumab 7Axitinib 7fludarabine 6aldesleukin 6cabozantinib 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Immunohistochemistry 5Gemcitabine 5peginterferon alfa-2b 4avelumab 4Nephrectomy 4Irinotecan 4Introns 4Gene Expression Profiling 4Capecitabine 4lenvatinib 3fludarabine phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Renal Cell × High-Energy Shock Waves × Clear all
NCT03821376 2024-10-10

Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS)

Indiana University

Phase 4 Terminated
12 enrolled 6 charts
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡